Kendle targets Asia with further Indian expansion
The company has had a presence in New Delhi, India since 2004 and has been expanding to allow its clients increased access to the nation’s favourable research conditions.
Asia/Pacific has been targeted by the company as a region that will help it maintain its impressive organic growth in a difficult operating environment.
Candace Kendle, PharmD, Chairman and CEO, said: "Expansion in the Asia/Pacific region, and India in particular, is essential to our continued success as a top global CRO.
“Our increased presence and capacity in the region will allow us to better meet the needs of our customers who are seeking to capitalise on India's cost-effective, yet high-quality clinical research capabilities to develop their compounds."
By continuing to expand outside of its regional base in New Delhi Kendle has given itself access to a greater proportion of the Indian population, which is one of the big attractions to companies looking to conduct trials in the country.
In addition to easing the recruitment of patients for clinical trials having access to a broad geographic area gives Kendle access to more of the talent pools spread around India.
Ahmedabad has become a focal point for the Indian pharmaceutical industry and multi-nationals looking to set up in the country.
This has been underpinned by the presence of renowned scientific education establishments and Zydus Cadila and Torrent Pharmaceuticals establishing their headquarters in the city.